A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence

Summary

The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells. The IGF-1 acts to promote muscle regeneration in the sphincter, which is expected to improve the function of the sphincter and thereby alleviate incontinence (urinary leakage).

Timeline

Start

2025-09

Primary completion

2027-11

Completion

2029-04

Outcome

Outcome not reported

Stopped (Enrollment): “The study has not enrolled study participants, and will not start enrolling, due to insufficient funding and is withdrawn from .”

Drugs

Indications